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Abstract 
Background: Insulinomas are the most common functional pancreatic neuroendocrine tumors, whereas histopatho‑
logical features do not predict their biological behaviour. In an attempt to better understand the molecular processes 
involved in the tumorigenesis of islet beta cells, the present study evaluated the expression of genes belonging to the 
hepatocyte growth factor and its receptor (HGF/MET) system, namely, MET, HGF; HGFAC and ST14 (encode HGF activa‑
tor and matriptase, respectively, two serine proteases that catalyze conversion of pro‑HGF to active HGF); and SPINT1 
and SPINT2 (encode serine peptidase inhibitors Kunitz type 1 and type 2, respectively, two inhibitors of HGF activator 
and of matriptase).
Methods: Quantitative real‑time reverse transcriptase polymerase chain reaction was employed to assess RNA 
expression of the target genes in 24 sporadic insulinomas: 15 grade 1 (G1), six grade 2 (G2) and three hepatic metasta‑
ses. Somatic mutations of MET gene were searched by direct sequencing of exons 2, 10, 14, 16, 17 and 19.
Results: Overexpression of MET was observed in the three hepatic metastases concomitantly with upregulation of 
the genes encoding HGF and matriptase and downregulation of SPINT1. A positive correlation was observed between 
MET RNA expression and Ki‑67 proliferation index while a negative correlation was detected between SPINT1 expres‑
sion and the mitotic index. No somatic mutations were found in MET gene.
Conclusion: The final effect of the increased expression of HGF, its activator (matriptase) and its specific receptor 
(MET) together with a decreased expression of one potent inhibitor of matriptase (SPINT1) is probably a contribution 
to tumoral progression and metastatization in insulinomas.
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Background
Insulinomas are the most common functional pancreatic 
neuroendocrine tumors (pNETs) with an estimated inci-
dence of 0.4 per 100,000 person-years [1]. They are usu-
ally benign, small, solitary and sporadic and are classified 
as malignant in the presence of local invasion or distant 
metastases, whereas histopathological features do not 
predict their biological behaviour [2].
Several studies have reported molecular alterations in 
the system comprising hepatocyte growth factor (HGF) 
and its tyrosine kinase receptor MET (HGF/MET sys-
tem) in different types of neoplasias [3, 4], in which 
inappropriate MET activation enhances proliferation, 
anti-apoptotic events, invasiveness and metastatization 
[5, 6]. The HGF/MET system has not been systematically 
investigated in insulinomas.
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In an attempt to better understand the molecular pro-
cesses involved in the tumorigenesis of islet beta cells, 
the aim of the present study was to assess the mRNA 
expression of genes belonging to the HGF/MET system 
in sporadic insulinomas and to correlate the expression 
findings with histopathological characteristics of the 
tumors. Besides MET and HGF, we also evaluated mRNA 
expression of the following components: (1) HGFAC and 
ST14, that encode HGF activator and matriptase, respec-
tively, two serine proteases that catalyze conversion of 
pro-HGF to active HGF and (2) SPINT1 and SPINT2, 
that encode serine peptidase inhibitors Kunitz type 1 and 
type 2, respectively, two potent inhibitors of HGF activa-
tor and of matriptase. To evaluate possible mechanisms 
involved in MET overexpression, the presence of somatic 
mutations in this gene was also examined.
Methods
Patients and tissue specimens
Tissue collection was performed in compliance with 
the Institutional Ethics Committee (CAPPesq) and in 
accordance to the Declaration of Helsinki, with informed 
consent being required from each subject. From 1999 
to 2011, 24 tumor tissues were obtained and processed 
as previously described [7]. Tumor fragments were col-
lected in sterile containers and immediately frozen in 
liquid nitrogen. The tumors were graded according to 
the classification system recommended by the Euro-
pean Neuroendocrine Tumor Society (ENETS) and the 
World Health Organization (WHO): (1) well-differenti-
ated grade 1 neuroendocrine tumor (G1; <2 mitoses/10 
HPF [high-power fields] and <3 % Ki-67 index); (2) well-
differentiated grade 2 neuroendocrine tumor (G2; 2–20 
mitoses/10HPF or 3-20  % Ki-67 index) and; (3) poor-
differentiated grade 3 neuroendocrine carcinoma (G3; 
>20 mitoses/10HPF or >20  % Ki-67 index) [8]. The his-
topathological characteristics of these insulinomas are 
shown in Additional file  1: Table  S1. The present series 
consisted of 15 G1 insulinomas, six G2 insulinomas and 
three hepatic metastases.
Quantitative real‑time reverse transcriptase polymerase 
chain reaction (qRT‑PCR)
Total RNA was extracted using the TriZol reagent (Invit-
rogen, Carlsbad, CA, USA) according to the manufactur-
er’s recommendations. RNA integrity and quantity were 
evaluated using the RNA 6000 Nano Assay with the Agi-
lent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, 
CA, USA) and only samples with an RNA Integrity Num-
ber (RIN) >7 were used. Complementary DNA (cDNA) 
was synthesized from total RNA. Briefly, first-strand 
cDNA synthesis was carried out with 1 μg of RNA, 1 μL 
of oligo(dT) primers (0.5  μg/μL), 1  μL of a solution 
with all four deoxyribonucleoside triphosphates (each at 
10  mM), and 10 ×  Superscript III reverse transcriptase 
(Invitrogen).
For TaqMan-based qRT-PCR, 100  ng of cDNA was 
added to 10 μL of 2 × Universal PCR Master Mix and 
to 1  μL of 20  ×  the specific primers and probe set 
(Applied Biosystems, Carlsbad, CA, USA). Fifty cycles 
of amplification were performed at 95  °C (15  s) and 
60  °C (1 min) in a StepOne Plus Realtime PCR system 
(Applied Biosystem). The following Assay on Demand 
primers and probes were used: Hs00300159_m1 (HGF), 
Hs01565584_m1 (MET), Hs00173526_m1 (HGFAC), 
Hs01058386_m1 (ST14), Hs00173678_m1 (SPINT1), 
Hs01070442_m1 (SPINT2) and Hs01652481_g1 
(PSMC6, which encodes the proteasome 26S subu-
nit, ATPase, 6) used as a control endogenous gene, as 
previously validated [7]. Human liver cDNA was used 
as positive control for HGF, MET, HGFAC and ST14 
genes expression and human placental tissue was used 
as a positive control for SPINT1 and SPINT2 genes 
expression. All samples were run in triplicate. Gene 
expression levels were analyzed by the mathematical 
model variation described by Livak and Schmittgen [9], 
2−ΔCt [10].
Mutational analysis
DNA from tumoral samples was extracted using the 
DNeasy kit (Qiagen, Valencia, CA, USA) according to 
the manufacturer’s instructions. For mutational analyses, 
exons 2, 10, 14, 16, 17 and 19 of MET proto-oncogene 
(GenBank accession number NM_000245) were ampli-
fied with specific primers (designed using the Primer 3 
software) for direct sequencing on an ABI 3130X Genetic 
Analyzer (Applied Biosystems) in 50 μl of PCR reaction 
mixture [100 ng genomic DNA, 0.2 mM of each primer, 
200 μM deoxynucleotides, 1× buffer and 1 U DNA Taq 
polymerase (GE Healthcare, Salt Lake City, UT, USA)]. 
PCR products were purified with ExoSAP IT (USB, 
Cleveland, OH, USA) and sequenced using the BigDye 
Terminator v1.1 Cycle Sequencing Kit (Applied Bio-
systems). Cycling conditions were as follows: 95  °C for 
5 min, 35 cycles of 95 °C for 30 s, followed by 56 °C (all 
exons) for 30 s and 72  °C for 10 min in a Thermocycler 
Model Veriti (Applied Biosystems). The sequences were 
analyzed using the Sequencher software, version 4.10.1.
Statistical analysis
Statistical tests were performed with JMP Version 10 
statistical computer program (SAS Institute, Cary, NC, 
USA). Data were evaluated by Kruskal–Wallis test fol-
lowed by Dunn’s multiple comparisons test. Analyses of 
correlations between the values of each gene expression 
and histopathological features were performed with the 
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Spearman correlation test. Statistical significance was 
fixed at probability levels of <0.05.
Results
Gene expression by qRT‑PCR
As shown in Fig.  1, a higher expression of MET 
(P  =  0.0115, Panel A), HGF (P  =  0.0183, Panel B) and 
ST14 (P = 0.0453, Panel C) mRNA was observed in the 
three metastases in comparison to G1 insulinomas. 
No HGFAC gene expression was detected in any stud-
ied tumoral sample (data not shown). The expression of 
SPINT1 mRNA (Panel D) was lower in the three metas-
tases in comparison to G1 insulinomas (P  =  0.0250), 
whereas no difference was detected in SPINT2 gene 
expression (Panel E). No statistically significant differ-
ences were observed between G1 and G2 insulinomas for 
any of the studied genes.
Additional file  2: Table  S2 depicts the statistically sig-
nificant correlations observed between tumoral his-
topathological variables and mRNA expression of the 
studied genes and also the correlations found among 
mRNA expression of the target genes. A positive correla-
tion was observed between MET mRNA expression and 
Ki-67 proliferation index (ρ = 0.4682; P = 0.0210) while 
a negative correlation was detected between SPINT1 
mRNA expression and the mitotic index (ρ  =  −0.4721; 
P  =  0.0174). High positive correlations were found 
between MET and HGF mRNA expression (ρ = 0.7827; 
P < 0.0001) and between MET and ST14 mRNA expres-
sion (ρ = 0.8272; P < 0.0001).
MET mutation analysis
Direct sequencing of the exons previously found mutated 
in other neoplasias (2, 10, 14, 16, 17 and 19) did not 
reveal somatic mutations in the MET gene in any tumoral 
sample.
Discussion
This study demonstrated the differential expression of 
four genes belonging to the HGF/MET system between 
G1 insulinomas and liver metastases of insulinomas, 
suggesting the participation of this pathway in the later 
stages of tumorigenesis.
The final effect of the increased expression of a growth 
factor (HGF), one of its activator (ST14) from the precur-
sor molecule and its specific receptor (MET) together 
with a decreased expression of one potent inhibitor of the 
growth factor activator (SPINT1) is probably a contri-
bution to tumoral progression, which is consistent with 
findings in other human neoplasias. In pancreatic carci-
noma cells, HGF seems to have a potent role in invasion 
and metastasis by exerting its antianoikis effect through 
phosphatidylinositol 3-kinase pathway [11]. In gastric 
cancers, for instance, the high expression of MET and 
HGF is associated with the development of metastases 
[12].
Findings that corroborate this hypothesis are the posi-
tive correlations observed between MET RNA expression 
and the Ki-67 proliferative index as well as the negative 
correlation between SPINT1 expression and the mitotic 
index. The correlations found among the RNA expression 
of the studied genes suggest interdependence among the 
different proteins that comprise the HGF/MET system.
In contrast to our findings, Wulbrand et al. [13] did not 
detect the expression of MET in ten insulinomas. How-
ever, only one case was described as metastatic and the 
methodology employed (RT-PCR) is less sensitive that 
the qRT-PCR used in the present study. Hansel et al. [14] 
have previously described increased expression of MET 
in metastatic versus non-metastatic pNETs, as well as in 
lymph node and in liver metastases, but their series did 
not include any metastatic insulinoma, only non-func-
tioning tumors, glucagonomas and gastrinomas. These 
data suggest that overexpression of MET is a molecular 
marker of malignancy not only of insulinomas, but also 
of other pNETs.
Activating mutations in the MET gene can promote 
the hyperactivity of this signalling pathway [15]. The fol-
lowing main oncogenic mutations have been described 
for this gene [4]: point mutations that lead to an alter-
native splicing, which results in a small protein without 
a PKC (protein kinase C) binding degradation site [16]; 
point mutations in the tyrosine kinase domain, which 
maintain the receptor constitutively active [17], and 
mutations that inactivate the negative regulatory Cbl (E3 
ubiquitin protein ligase) binding site, which drive MET 
to ubiquitination, endocytosis, and subsequent degrada-
tion [18].
To investigate whether the presence of somatic muta-
tions would be involved in MET upregulation, direct 
sequencing of exons previously reported as mutated in 
other cancer types was performed and no mutations were 
detected. Alternative explanations for the observed MET 
overexpression could be gene amplification, as reported 
in non-small-cell lung carcinoma [19] and in ovarian ade-
nocarcinoma [20], gains of 7q (MET gene is located on 
7q31) that are known to be involved in the progression of 
insulinomas and other pNETs [21], and epigenetic modi-
fications, such as loss of DNA methylation, already iden-
tified in a mouse model of hepatocellular carcinoma [22].
An interesting finding of the present study was the 
absence of RNA expression of HGFAC, considered the 
most powerful activator of pro-HGF in HGF [23], indi-
cating that in insulinomas, matriptase (and maybe other 
proteins not evaluated in this study, such as hepsin [24] ) 
is responsible for pro-HGF proteolysis. A lower RNA 
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expression of the inhibitor of matriptase SPINT1 was 
detected in the insulinoma metastases, potentially con-
tributing to increased activity of matriptase to participate 
in HGF activation.
The main limitation of this study is the small number 
of metastasis samples, due to the rarity of this condi-
tion. Nevertheless, the differential expression of not only 
one but four different genes of HGF/MET system, the 
Fig. 1 mRNA expression values of MET (a), HGF (b), ST14 (c), SPINT1 (d), and SPINT2 (e) in insulinomas graded according to 2014 ENETS/WHO clas‑
sification (G1, G2 and hepatic metastases). Box diagram comparing relative mRNA expression levels of genes; the horizontal line within the box plot 
represents the median value, the box plot limits refer to 25th–75th percentiles, and the box plot bars include the 10th–90th percentiles for mRNA 
levels
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observed correlations between MET and SPINT1 mRNA 
expression and tumor histopathological features and 
the previous identification of MET as overexpressed in 
other metastatic pNETs [14] suggest the participation of 
the HGF/MET pathway in the later stages of insulinoma 
tumorigenesis. The confirmation of our findings in larger 
series could allow the development of strategies oriented 
to this system as a potential target to control the progres-
sion of insulinomas.
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